The growing interest in psychedelics has led to an abundance of retreat options, but they won’t all be safe and ...

A new FDA regulatory pathway could accelerate approval of psychedelic therapies for resistant depression and PTSD, and ...

President Trump issued an executive order to fast-track psychedelic therapies like ibogaine to treat PTSD and other mental ...

WASHINGTON (AP) — Surging interest in the purported benefits of psychedelic drugs has given rise to books, documentaries and ...

The Senate bill proposes to open a limited psychedelic-assisted therapy pilot program established in 2022 to people who are ...

Following an executive order from President Trump, the FDA is fast-tracking several psychedelic studies for the treatment of ...

FDA fast‑tracks three psychedelic drugs after Trump order speeding research on depression and PTSD treatments.

Research and policy changes are driving new interest in psychedelic treatments like psilocybin for mental health conditions.

Mounting interest in the potential benefits of psychedelic drugs has led to a rise in psychedelic retreats around the world.

The Food and Drug Administration says it will offer ultra-fast review to three psychedelic drugs being studied for ...

Shares of psychedelic drug developers rose after Trump signed an executive order directing health regulators to speed up ...

Psychedelic treatments receive more positive media coverage than antidepressants. What does this mean for patient care?